Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Culture

Sephardi Mutations Raise Calls for Expanded Test

Researchers have discovered the first mutations responsible for hereditary breast and ovarian cancer among “pure” Sephardi Jews, leading to calls for a more comprehensive genetic test for high-risk women in Israel.

“When a woman of Sephardic origin used to come to our clinic, we would tell her, ‘You are not Ashkenazi, so you might have a mutation in BRCA1 or BRCA2, but it is hard to find it,’” said Dr. Michal Sagi, a genetic counselor at Hadassah Medical Center in Jerusalem, referencing the two genes that predispose women to breast and ovarian cancer.

“Now, when a Sephardic woman comes to the clinic, I say, ‘If you have a mutation, it is probably one of the permutations we found. Let’s check to see if you carry them.’”

In the mid-1990s, scientists first showed that about one in 40 Ashkenazi Jewish women have mutations in the two BRCA genes and that these mutations are associated with a 50% to 85% chance of developing breast cancer and a slightly lower but still appreciable lifetime risk of ovarian cancer.

Most incidences of these cancers are still sporadic with no genetic cause, even among Ashkenazi Jews. But given the heightened genetic risk in the Ashkenazi community, physicians almost immediately started screening women with strong family histories of breast or ovarian cancer for the mutations.

It wasn’t just an Ashkenazi problem, though. Within a few years, researchers discovered unique BRCA mutations in Jewish women from Iraq, Iran, Yemen and Afghanistan — which prompted clinics in Israel, where most of the world’s Middle Eastern Jews live, to start offering genetic testing to Jewish women with these genetic backgrounds, too.

Yet, for over a decade, Sephardic women whose ancestors fled Spain and Portugal more than 500 years ago had no test of their own. That may soon change, however, thanks to a recent discovery by Sagi and her colleagues.

Sagi’s team began its inquiry after tests revealed the same two mutations in a few unrelated Sephardic women with strong family histories of breast and ovarian cancer. Sensing a pattern, the team delved into the Hadassah archives and tested for the same irregularities in a much larger collection of blood samples taken from Sephardi cancer patients.

Reporting online late last year in the journal Familial Cancer, the researchers discovered the two never-before-seen mutations — one in BRCA1, the other in BRCA2 — in six of 177 Sephardi women.

This mutation prevalence is on par with that seen among Ashkenazi women. However, when researchers ran the data for DNA samples of only those Sephardi women whose families had a history of breast cancer, the number shot up: Almost one in three samples contained both mutations.

Now, the study authors are calling on Israel’s public health plan to provide free testing for these Sephardi mutations, in addition to those already on the so-called “Jewish panel” — which includes the five mutations specific to Ashkenazi, Iraqi, Iranian, Yemeni and Afghani Jews.

Meanwhile, Bracha, an Israeli breast and ovarian cancer awareness group, is urging the government to go one step further and pay for full gene sequencing in high-risk women, including Sephardi individuals, whose mutation tests come back negative. U.S. insurance companies already commonly cover BRCA gene sequencing, but women in Israel typically have to pay about $3,000 out of pocket for such tests.

“We continue to fight for this minority group,” said Bracha founder Lisa Cohen, of Sephardi women. “We have known for a long time that it is not just Ashkenazi Jews with mutations in the BRCA genes.”

Contact Naomi Zeveloff at zeveloff@forward.com

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and the protests on college campuses.

Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.

Make a gift of any size and become a Forward member today. You’ll support our mission to tell the American Jewish story fully and fairly. 

— Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at editorial@forward.com, subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.

Exit mobile version